Nanobiotix SA (NBTX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Oct31

Nanobiotix SA Enters into Royalty Monetization Agreement with Healthcare Royalty

07:01

Oct24

Nanobiotix transfers head and neck cancer trial control to Johnson & Johnson

06:00

Oct4

Nanobiotix SA ADR Reports Significant H1 2025 Revenue Growth, Narrowed Net Loss

03:56

Oct1

Nanobiotix SA released FY2025 Semi-Annual Earnings on September 30 (EST), actual revenue USD 30.01 M (forecast USD 8.154 M), actual EPS USD -0.1278 (forecast USD -0.4448)

03:00

Nanobiotix SA released FY2025 Q2 earnings on September 30 (EST), actual revenue USD 15.59 M, actual EPS USD -0.0664

03:00

Nanobiotix SA released FY2025 Q1 earnings on September 30 (EST), actual revenue USD 14.42 M, actual EPS USD -0.0614

03:00

Schedules & Filings

Schedules

Filings

Sep30

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 15.59 M, Net Income -3.151 M, EPS -0.0664

Apr2

Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue -8.57 M, Net Income -24.06 M, EPS -0.5088

Sep18

Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 4.975 M, Net Income -11.72 M, EPS -0.2485

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change